Eli Lilly CEO: One-Third of Patients on New GLP-1 Drug Take Fondayo

The disclosure is notable less for the headline share than for the fact that a meaningful slice of patients is being prescribed the new drug alongside an existing therapy rather than as a straight substitute — a pattern that matters for how quickly a launch converts into durable revenue. It affects Lilly's competitive positioning in a market where prescribing habits, not just approvals, determine uptake. The open question is whether this combination behavior reflects clinical need or transitional prescribing, and whether the company provides more detail on the patient population and timeframe behind the figure.